Divi's Labs' Vizag plant banned from shipping to US
Indian API firm Divi’s Laboratories has been banned from shipping drug ingredients made at its Vizag plant to the US.
Archives for March 23, 2017
Axim taps CRO for cannabinoid product development and clinical trials
Axim Biotech has contracted an ophthalmology CRO to support upcoming product development and clinical trials for its cannabinoid-based therapeutics.
Chiron AS cleared to make carfentanyl for opioid researchers
Reference material manufacturer Chiron AS has been cleared to make carfentanyl for opioid researchers working in Europe.
Compounding firm looks at NDA opportunity for reformulation of Mallinckrodt's H.P. Acthar
Imprimis Pharmaceuticals says it is evaluating pursuing New Drug Application (NDA) status for some of its product reformulations through the US FDA 505(b)(2) development pathway.
update
PPD launches CRA apprenticeship program
PPD is offering "on-the-job" training through a new, competency-based clinical research associate (CRA) apprenticeship program.